Clearmind Medicine Inc. (Nasdaq: CMND), a Vancouver-based clinical-stage biotech focused on non-hallucinogenic, neuroplastogen-derived therapeutics, has agreed to acquire a 51% controlling stake in Charging Robotics for $2.5 million. As a condition of the transaction, Clearmind will extend a $1.5 million loan bearing 4% annual interest, bringing the total commitment to $4 million. Charging Robotics develops proprietary wireless charging technology delivering up to 10 kW of continuous power for automated parking facilities, autonomous mobile platforms and robotaxis, where conventional plug-in infrastructure is impractical. The transaction is expected to close during the week of Sept. 7, 2026, subject to customary closing conditions. Clearmind shares fell 8.82% to $1.55 in Friday premarket trading, near their 52-week low of $1.43, as investors assessed the company's expansion beyond its core pharmaceutical business.